688266 Stock Overview

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. More details

688266 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	5/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 51.4% below our estimate of its fair value

Earnings are forecast to grow 127.33% per year

Earnings have grown 10.3% per year over the past 5 years

Risk Analysis

No risks detected for 688266 from our risk checks.

My Notes

Capture your thoughts, links and company narrative

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Competitors

Pacific Shuanglin Bio-pharmacy

SZSE:000403

CN¥15.5b

Anhui Anke Biotechnology (Group)

SZSE:300009

CN¥14.8b

Xiamen Amoytop Biotech

SHSE:688278

CN¥30.1b

Sunshine Guojian Pharmaceutical (Shanghai)

SHSE:688336

CN¥13.3b

Price History & Performance

Summary of share price highs, lows and changes for Suzhou Zelgen BiopharmaceuticalsLtd
Historical stock prices
Current Share Price	CN¥61.70
52 Week High	CN¥79.99
52 Week Low	CN¥33.20
Beta	0.61
1 Month Change	-7.86%
3 Month Change	3.75%
1 Year Change	23.87%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	23.47%

Recent updates

Shareholder Returns

	688266	CN Biotechs	CN Market
7D	-0.5%	-1.7%	-0.5%
1Y	23.9%	-19.8%	9.2%

Return vs Industry: 688266 exceeded the CN Biotechs industry which returned -19.6% over the past year.

Return vs Market: 688266 exceeded the CN Market which returned 10.8% over the past year.

Price Volatility

Is 688266's price volatile compared to industry and market?
688266 volatility
688266 Average Weekly Movement	7.9%
Biotechs Industry Average Movement	8.8%
Market Average Movement	8.8%
10% most volatile stocks in CN Market	13.0%
10% least volatile stocks in CN Market	5.7%

Stable Share Price: 688266 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 688266's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2009	858	Zelin Sheng	www.zelgen.com

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China. It offers donafenib tablets; recombinant human thrombin for topincal use; jacktinib tablets; and recombinant human thyroid-stimulating hormone for injection; obeticholic acid magnesium tablets; ZG19018 tablets; ZG005 powder for injection; and alkotinib capsules for the treatment of liver cancer, non-small cell lung cancer, small cell lung cancer, colorectal cancer, thyroid cancer, and neuroendocrine cancer, as well as multiple therapeutic areas, such as bleeding, hepatobiliary diseases, and autoimmune diseases.

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Fundamentals Summary

How do Suzhou Zelgen BiopharmaceuticalsLtd's earnings and revenue compare to its market cap?
688266 fundamental statistics
Market cap	CN¥16.33b
Earnings (TTM)	-CN¥174.40m
Revenue (TTM)	CN¥488.45m

33.4x

P/S Ratio

-93.7x

P/E Ratio

Is 688266 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
688266 income statement (TTM)
Revenue	CN¥488.45m
Cost of Revenue	CN¥37.00m
Gross Profit	CN¥451.45m
Other Expenses	CN¥625.85m
Earnings	-CN¥174.40m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.66
Gross Margin	92.43%
Net Profit Margin	-35.70%
Debt/Equity Ratio	68.6%

How did 688266 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/26 08:08
End of Day Share Price	2024/12/26 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ziyu He	China International Capital Corporation Limited
Shitong Han	Citic Securities Co., Ltd.
Yinhao Tang	Citic Securities Co., Ltd.